Chiron acquires Sagres Discovery
Chiron Corp has acquired fellow USA-based, privately-held company SagresDiscovery, which focuses on the discovery and validation of targets with potential application in cancer therapeutics. Financial terms were undisclosed.
The company sees the move as supporting its efforts to develop a broader pipeline, and intends to use Sagres' Oncogenome, a comprehensive assembly of genes that cause cancer, to discover new targets for development.
Kenneth Bair, senior vice president and head of research at Chiron BioPharmaceuticals, said: "Sagres has a wealth of in vivo validated targets, including kinases and antibodies, that will increase both the quantity and quality of targets available to us for development. With the wealth of targets from Sagres, we expect to be able to maximize the value of our collaboration with Xoma (Marketletter March 8) and our small-molecule drug discovery program for the development and commercialization of new drugs for the treatment of cancer."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze